BCL2 and diffuse large B-cell lymphoma: Among these biomarkers, FOXP1 and BCL2 have been shown to associate with worse prognosis in DLBCL cases.9, 42, 43, 46 In OSdlbcl, we found the FOXP1 (HR = 1.73, P < .01) and BCL2 (HR = 1.47, P = .03) (Table 2, Figure 1) were consistent to be adverse prognostic biomarkers for DLBCL patients.